HC Wainwright Has Negative Forecast for Cybin Q2 Earnings

Key Points

• HC Wainwright has revised its earnings estimates for Cybin, forecasting a Q2 2026 loss of ($0.74) per share, down from a prior estimate of ($0.56).
• Institutional investors have increased their stakes in Cybin, with 17.94% of the stock currently owned by institutional investors, indicating growing confidence in the company.
• Cybin's stock has a consensus rating of "Buy" with a price target of $85.00, despite recent earnings estimate downgrades.

Cybin Inc. (NYSE:CYBN - Free Report) - Analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Cybin in a research note issued on Monday, August 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.74) per share for the quarter, down from their prior estimate of ($0.56). The consensus estimate for Cybin's current full-year earnings is ($4.76) per share. HC Wainwright also issued estimates for Cybin's Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($1.57) EPS, FY2029 earnings at $5.17 EPS and FY2030 earnings at $7.47 EPS.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald raised Cybin to a "strong-buy" rating in a research report on Tuesday, May 13th. Canaccord Genuity Group decreased their target price on Cybin from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $85.00.

Cybin Price Performance

CYBN stock traded up $0.3750 during trading on Wednesday, reaching $7.5250. 476,982 shares of the stock traded hands, compared to its average volume of 321,184. The business's 50 day moving average price is $7.68 and its 200-day moving average price is $7.53. Cybin has a 52-week low of $4.81 and a 52-week high of $13.88. The firm has a market capitalization of $177.51 million, a PE ratio of -1.73 and a beta of 0.68.

Hedge Funds Weigh In On Cybin

A number of institutional investors have recently added to or reduced their stakes in the company. Tang Capital Management LLC lifted its holdings in Cybin by 232.5% in the 4th quarter. Tang Capital Management LLC now owns 1,330,097 shares of the company's stock worth $11,731,000 after buying an additional 930,097 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Cybin in the fourth quarter valued at about $7,938,000. Acorn Capital Advisors LLC purchased a new position in Cybin in the fourth quarter valued at about $6,477,000. DCF Advisers LLC purchased a new position in Cybin in the first quarter valued at about $1,281,000. Finally, Bollard Group LLC purchased a new position in Cybin in the second quarter valued at about $1,317,000. Institutional investors and hedge funds own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.